ZURICHA drug developed by Novartis AG significantly improved the symptoms of patients with a debilitating inflammatory disease according to data presented by the Swiss pharmaceutical giant on Saturday setting up the prospect of another bigselling product for its portfolio Baselbased Novartis said AIN also known as secukinumab reduced symptoms of ankylosing spondylitis in more than  of patients receiving the drug in two latestage tests By comparison less than  of patients receiving a placebo showed improvements
  